Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The presence of moieties denoting viral infection is crucial to mount powerful cytotoxic T-cell immune responses acting through innate receptors such as Toll-like receptor 3 (TLR3). For cancer immunotherapy, several safe analogues of viral double-stranded RNA (dsRNA) are under clinical development following compelling evidence for efficacy in mouse models.

Original publication

DOI

10.1158/1078-0432.ccr-24-0938

Type

Journal article

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Publication Date

06/2024

Addresses

Clinica Universidad de Navarra, CIBERONC, Pamplona, Navarra, Spain.